



April 6, 2010

## **Medical Compression System continues to expand its reach in the US, penetrating four more medical centers in March**

**Approximately 2,000 relevant medical procedures are performed annually at these medical centers, and MCS expects its penetration rate to reach about 20% in the first year**

**Medical Compression System (MCS)**, engaged in the field of non-invasive medical devices and traded on the Tel Aviv Stock Exchange, announced today (Tuesday, April 6, 2010) that in March four more medical centers in the USA had selected its product, ActiveCare + S.F.T.<sup>®</sup>, for the prevention of DVT following orthopedic surgery. The medical centers are located in Missouri, Oregon, Ohio and Minnesota.

Approximately 2,000 relevant medical procedures are performed annually at these medical centers, and MCS expects its penetration rate to reach about 20% in the first year.

According to Adi Dagan, CEO of Medical Compression System: "The publication of the outstanding trial results in the leading medical journal JBJS, just prior to the opening of the AAOS 2010 Annual Meeting, generated a great deal of interest and inquiry. We believe that these inquiries will lead to our entry into additional centers in the coming months."

### **About MCS**

MCS is engaged in the field of non-invasive medical devices and has developed a device to prevent deep vein thrombosis (DVT) as a result of trauma or surgical intervention. The company has FDA approval for the sales and marketing of its products in the United States and CE approval for sales and marketing of its products in Europe.

### **Forward-Looking Statements**

The Company's estimates in this publication, including with respect to the volume of its activity, constitute forward-looking information as defined in the Securities Law, 5728 – 1968 and it is not at all certain that said statements will materialize. The Company's estimates are based on business assumptions, past experience and professional information. These estimates may not materialize, in whole or in part, or differ materially from what the Company expects, for various reasons, including a change in market trends, competition, global or local economic situation and regulatory changes.